Lee's Pharmaceutical Holdings (SEHK:950) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

950 Panoramica delle azioni

Lee's Pharmaceutical Holdings Limited, una holding di investimento, sviluppa, produce, commercializza e vende prodotti farmaceutici principalmente nella Repubblica Popolare Cinese.

Informazioni sull'azienda

950 analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	1/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 16.14% all'anno

Analisi del rischio

Gli utili sono diminuiti del 3.4% all'anno negli ultimi 5 anni

Grandi elementi una tantum che incidono sui risultati finanziari

I margini di profitto (1.6%) sono inferiori rispetto allo scorso anno (4.2%)

Non ha una capitalizzazione di mercato significativa ( HK$701M )

Lee's Pharmaceutical Holdings Limited Concorrenti

Lansen Pharmaceutical Holdings

SEHK:503

HK$750.6m

Jilin Province Huinan Changlong Bio-pharmacy

SEHK:8049

HK$801.2m

Zhongzhi Pharmaceutical Holdings

SEHK:3737

HK$820.4m

JBM (Healthcare)

SEHK:2161

HK$725.0m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Lee's Pharmaceutical Holdings
Prezzi storici delle azioni
Prezzo attuale dell'azione	HK$1.15
Massimo di 52 settimane	HK$1.75
Minimo di 52 settimane	HK$1.00
Beta	0.90
1Variazione di 1 mese	1.77%
Variazione a 3 mesi	-0.86%
Variazione di 1 anno	-13.53%
3Variazione a 3 anni	-70.81%
Variazione a 5 anni	-67.24%
Variazione dall'IPO	121.15%

Notizie e aggiornamenti recenti

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Aug 07

Recent updates

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Aug 07

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

May 21

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29

What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

Jan 12

Have Insiders Sold Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Recently?

Dec 22

Don't Ignore The Fact That This Insider Just Sold Some Shares In Lee's Pharmaceutical Holdings Limited (HKG:950)

Dec 08

Rendimenti per gli azionisti

	950	HK Pharmaceuticals	HK Mercato
7D	-6.5%	2.1%	1.4%
1Y	-13.5%	11.7%	4.6%

Ritorno vs Industria: 950 ha avuto una performance inferiore rispetto al Hong Kong Pharmaceuticals che ha registrato un rendimento 13.4 % nell'ultimo anno.

Rendimento vs Mercato: 950 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 6.2 % nell'ultimo anno.

Volatilità dei prezzi

Is 950's price volatile compared to industry and market?
950 volatility
950 Average Weekly Movement	5.0%
Pharmaceuticals Industry Average Movement	5.0%
Market Average Movement	6.3%
10% most volatile stocks in HK Market	13.2%
10% least volatile stocks in HK Market	3.4%

Prezzo delle azioni stabile: 950 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 5% ) di 950 è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1994	1,057	n/a	www.leespharm.com

Lee's Pharmaceutical Holdings Limited, una holding di investimento, sviluppa, produce, commercializza e vende prodotti farmaceutici principalmente nella Repubblica Popolare Cinese. Si concentra su diverse aree patologiche, tra cui cardiovascolare, salute della donna, pediatria, malattie rare, oncologia, dermatologia e ostetricia. Opera attraverso i segmenti Prodotti proprietari e generici e Prodotti in licenza.

Lee's Pharmaceutical Holdings Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Lee's Pharmaceutical Holdings con la sua capitalizzazione di mercato?
950 statistiche fondamentali
Capitalizzazione di mercato	HK$677.16m
Guadagni(TTM)	HK$16.70m
Ricavi(TTM)	HK$1.05b

40.6x

Rapporto P/E

0.6x

Rapporto P/S

950 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
950 Conto economico (TTM)
Ricavi	HK$1.05b
Costo del fatturato	HK$501.72m
Profitto lordo	HK$551.31m
Altre spese	HK$534.61m
Guadagni	HK$16.70m

Ultimi guadagni dichiarati

Dec 31, 2023

Prossima data di guadagno

Aug 28, 2024

Utile per azione (EPS)	0.028
Margine lordo	52.35%
Margine di profitto netto	1.59%
Rapporto debito/patrimonio netto	9.8%

Come si è comportato 950 nel lungo periodo?

Vedi performance storica e confronto

Dividendi

1.6%

Rendimento attuale del dividendo

63%

Rapporto di remunerazione

950 Panoramica delle azioni

Premi

Analisi del rischio

Lee's Pharmaceutical Holdings Limited Concorrenti

SEHK:503

HK$750.6m

SEHK:8049

HK$801.2m

SEHK:3737

HK$820.4m

SEHK:2161

HK$725.0m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong

Board Member recently bought HK$59k worth of stock

Board Member recently bought HK$117k worth of stock

Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director

Recent updates

Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong

Board Member recently bought HK$59k worth of stock

Board Member recently bought HK$117k worth of stock

Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director

Board Member recently bought HK$120k worth of stock

Board Member recently bought HK$61k worth of stock

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

Upcoming dividend of HK$0.01 per share

Board Member recently bought HK$130k worth of stock

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Board Member recently bought HK$123k worth of stock

New minor risk - Market cap size

Board Member recently bought HK$75k worth of stock

Investor sentiment improves as stock rises 15%

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Board Member recently bought HK$50k worth of stock

Board Member recently bought HK$113k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock

Investor sentiment improves as stock rises 17%

Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock

Investor sentiment improves as stock rises 18%

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

New minor risk - Market cap size

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Upcoming dividend of HK$0.01 per share at 1.3% yield

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Price target decreased to HK$1.80

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022

Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa

Price target decreased to HK$1.80

Upcoming dividend of HK$0.01 per share

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022

Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Board Member recently bought HK$231k worth of stock

Lee's Pharmaceutical Holdings Limited Announces That Teglutik Obtains Drug Registration Certificate

Board Member recently bought HK$381k worth of stock

First quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.07 in 1Q 2021)

Lee's Pharmaceutical Holdings Limited's Natulan Obtains Drug Registration Certificate